| treatment |
|
comparator |
All cause death | Coronary event | Adverse events | Cardiovascular death | Fatal MI | Major bleeding | Non fatal MI | stroke (fatal and non fatal) |
|
|
| Aspirin | post myocardial infarction, in all type of patients | vs placebo | NS | - | - | by 28% | by 58% | - | by 29% | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.90 [0.80 1.01] | p=1.00 | 0 | 12636 | 8 | CDPA, Cardiff I, Cardiff II, Vogel, AMIS, GAMIS, PARIS, JAMIS, | | Coronary event | no data | | Adverse events | no data | | Cardiovascular death | 0.72 [0.56 0.93] | p=0.04 | 0 | 4565 | 4 | CDPA, Vogel, PARIS, JAMIS, | | Fatal MI | 0.42 [0.22 0.80] | p=0.04 | 0 | 1966 | 2 | Vogel, GAMIS, | | Major bleeding | no data | | Non fatal MI | 0.71 [0.60 0.84] | p=0.04 | 0 | 9715 | 6 | CDPA, Vogel, AMIS, GAMIS, PARIS, JAMIS, | | stroke (fatal and non fatal) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CDPA, 1976 | Aspirin (324 mg) 3x/d | Placebo | MI survivors | | Cardiff I, 1974 | Aspirin (300 mg) 1x/d | Placebo | MI survivors | | Cardiff II, 1979 | Aspirin (300 mg) 3x/d for one year | Placebo | patients with myocardial infarction | | Vogel, 1979 | Aspirin (1.5 g daily) on an average period of 22 months
| Placebo
| | | AMIS, 1980 | Aspirin (500 mg) 2x/d for at least 3 years | Placebo | men and women who had had a documented myocardial infarction | | GAMIS, 1980 | Aspirin (500 mg) 3x/d for 2 years | Placebo | patients who had survived a myocardial infarction for 30-42 days | | PARIS, 1980 | Aspirin (324 mg) 3x/d | Placebo | patients who had recovered from myocardial infarction | | JAMIS, 1999 | Aspirin (81 mg) 1x/d | No antiplatelets | patients with AMI within 1 month from the onset of symptoms |
|
| Clopidogrel | post myocardial infarction, in all type of patients | vs aspirin | NS | - | - | - | NS | - | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.98 [0.87 1.10] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Coronary event | no data | | Adverse events | no data | | Cardiovascular death | no data | | Fatal MI | 0.71 [0.50 1.00] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Major bleeding | no data | | Non fatal MI | 0.85 [0.71 1.00] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | stroke (fatal and non fatal) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CAPRIE, 1996 | Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years | Aspirin (325 mg) 1x/d | patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease |
|
| Dipyridamol | post myocardial infarction, in all type of patients | vs placebo | NS | - | - | NS | - | - | by 31% | by 39% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.92 [0.74 1.15] | p=1.00 | 0 | 4344 | 2 | PARIS, PARIS-II, | | Coronary event | no data | | Adverse events | no data | | Cardiovascular death | 0.88 [0.70 1.11] | p=1.00 | 0 | 4344 | 2 | PARIS, PARIS-II, | | Fatal MI | no data | | Major bleeding | no data | | Non fatal MI | 0.69 [0.54 0.88] | p=0.04 | 0 | 4344 | 2 | PARIS, PARIS-II, | | stroke (fatal and non fatal) | 0.61 [0.38 0.99] | p=0.04 | 0 | 4344 | 2 | PARIS, PARIS-II, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d | Placebo | patients who had recovered from myocardial infarction | | PARIS-II, 1986 | Aspirin (330 mg) + dipyridamole (75 mg) 3x/d | Placebo | patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously |
|
| Dipyridamol | post myocardial infarction, in all type of patients | vs aspirin | NS | NS | - | NS | - | - | NS | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.02 [0.75 1.40] | p=1.00 | 0 | 1620 | 1 | PARIS, | | Coronary event | 1.05 [0.80 1.36] | p=1.00 | 0 | 1620 | 1 | PARIS, | | Adverse events | no data | | Cardiovascular death | 0.99 [0.70 1.38] | p=1.00 | 0 | 1620 | 1 | PARIS, | | Fatal MI | no data | | Major bleeding | no data | | Non fatal MI | 1.14 [0.79 1.66] | p=1.00 | 0 | 1620 | 1 | PARIS, | | stroke (fatal and non fatal) | 1.11 [0.45 2.75] | p=1.00 | 0 | 1620 | 1 | PARIS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d | Aspirin (324 mg) 3x/d | patuents who had recovered from myocardial infarction |
|
